Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex.

Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, Kojetin DJ, Dodge JA, Burris TP, Griffin PR.

Nat Struct Mol Biol. 2011 May;18(5):556-63. doi: 10.1038/nsmb.2046. Epub 2011 Apr 10.

2.

Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer.

Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Garcia-Ordonez RD, Pascal BD, Burris TP, Dodge JA, Griffin PR.

Structure. 2010 Oct 13;18(10):1332-41. doi: 10.1016/j.str.2010.07.007.

3.

A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia.

Sato M, Lu J, Iturria S, Stayrook KR, Burris LL, Zeng QQ, Schmidt A, Barr RJ, Montrose-Rafizadeh C, Bryant HU, Ma YL.

J Bone Miner Res. 2010 Jun;25(6):1326-36. doi: 10.1002/jbmr.15.

4.

Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta.

Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris LL, Khorasanizadeh S, Burris TP, Rastinejad F.

Nat Struct Mol Biol. 2007 Dec;14(12):1207-13. Epub 2007 Nov 25.

5.

The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand.

Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, Cheng CC, Zink RW, Barr RJ, Hepler CD, Krishnan V, Bullock HA, Burris LL, Galvin RJ, Bramlett K, Stayrook KR.

Mol Pharmacol. 2005 Mar;67(3):948-54. Epub 2004 Dec 15.

PMID:
15602004
6.

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB.

Cancer Res. 2001 Dec 1;61(23):8412-5.

Supplemental Content

Loading ...
Support Center